Home › Funds › Parkman Healthcare Partners LLC › DRUG
Parkman Healthcare Partners LLC position in DRUG
BRIGHT MINDS BIOSCIENCES INC · Health Care
Parkman Healthcare Partners LLC reported holding 205,053 shares of DRUG (BRIGHT MINDS BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$14.4M, representing 1.47% of its reported portfolio and ranking #28 among its reported holdings. Parkman Healthcare Partners LLC has disclosed DRUG holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's DRUG position evolved
Parkman Healthcare Partners LLC first disclosed a stake in DRUG in Q1 2026 at 40,098 shares (US$2.9M). The position peaked in Q2 2026 at 205,053 shares, worth US$14.4M. Across 2 filings, Parkman Healthcare Partners LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 205,053 shares valued at US$14.4M — an increase of 164,955 shares quarter over quarter.. Notable position changes include a 411% increase in Q2 2026 (shares fell 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 40.10K | $2.93M | New |
| Q2 2026 | 205.05K | $14.39M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DRUG and 13F data
DRUG (BRIGHT MINDS BIOSCIENCES INC) is a Health Care company. 77 other funds we track also report a position in DRUG — the largest reported positions include Cormorant Asset Management, LP (US$63.2M), Vivo Capital, LLC (US$39.1M), Vestal Point Capital, LP (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DRUG
- Cormorant Asset Management, LP 900.00K sh · $63.18M · Q2 2026
- Vivo Capital, LLC 557.17K sh · $39.11M · Q2 2026
- Vestal Point Capital, LP 545.00K sh · $38.26M · Q2 2026
- BRAIDWELL LP 483.82K sh · $33.96M · Q2 2026
- MPM BioImpact LLC 202.11K sh · $14.19M · Q2 2026
- GREAT POINT PARTNERS LLC 109.60K sh · $7.69M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 92.75K sh · $6.51M · Q2 2026
- Ikarian Capital, LLC 88.95K sh · $6.24M · Q2 2026
- Sio Capital Management, LLC 73.95K sh · $5.19M · Q2 2026
- B Group, Inc. 67.50K sh · $4.74M · Q2 2026
- Artia Global Partners LP 38.41K sh · $2.70M · Q2 2026
- KVP Capital Advisors, LP 31.81K sh · $2.23M · Q2 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held DRUG?
Parkman Healthcare Partners LLC has disclosed DRUG holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Parkman Healthcare Partners LLC's current position in DRUG?
As of Q2 2026, Parkman Healthcare Partners LLC holds 205.05K shares of DRUG (BRIGHT MINDS BIOSCIENCES INC), valued at $14.39M, representing 1.47% of its reported portfolio and ranking #28.
Has Parkman Healthcare Partners LLC been buying or selling DRUG?
In the latest 13F filing (Q2 2026), Parkman Healthcare Partners LLC increased its position in DRUG. The position peaked in Q2 2026 at 205.05K shares.
Which other funds hold DRUG?
Other major institutional holders of DRUG include Cormorant Asset Management, LP, Vivo Capital, LLC, Vestal Point Capital, LP, among 77 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.